These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 20002082)

  • 1. Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers.
    Lim KS; Cho JY; Kim BH; Kim JR; Kim HS; Kim DK; Kim SH; Yim HJ; Lee SH; Shin SG; Jang IJ; Yu KS
    Br J Clin Pharmacol; 2009 Dec; 68(6):883-90. PubMed ID: 20002082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
    Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
    Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.
    Noh YH; Lim HS; Jin SJ; Kim MJ; Kim YH; Sung HR; Choi HY; Bae KS
    Clin Ther; 2012 May; 34(5):1182-94. PubMed ID: 22534255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase IV inhibitor LC15-0444 and pioglitazone in healthy volunteers.
    Kim SE; Yi S; Shin KH; Kim TE; Kim MJ; Kim YH; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    Int J Clin Pharmacol Ther; 2012 Jan; 50(1):17-23. PubMed ID: 22192641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.
    Gu N; Park MK; Kim TE; Bahng MY; Lim KS; Cho SH; Yoon SH; Cho JY; Jang IJ; Yu KS
    Drug Des Devel Ther; 2014; 8():1709-21. PubMed ID: 25336915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes.
    Rhee EJ; Lee WY; Yoon KH; Yoo SJ; Lee IK; Baik SH; Kim YK; Lee MK; Park KS; Park JY; Cha BS; Lee HW; Min KW; Bae HY; Kim MJ; Kim JA; Kim DK; Kim SW
    Diabetes Obes Metab; 2010 Dec; 12(12):1113-9. PubMed ID: 20977584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study.
    Kim TE; Lim KS; Park MK; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2012 Sep; 34(9):1986-98. PubMed ID: 22943970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.
    Heise T; Graefe-Mody EU; Hüttner S; Ring A; Trommeshauser D; Dugi KA
    Diabetes Obes Metab; 2009 Aug; 11(8):786-94. PubMed ID: 19476474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects.
    Retlich S; Duval V; Ring A; Staab A; Hüttner S; Jungnik A; Jaehde U; Dugi KA; Graefe-Mody U
    Clin Pharmacokinet; 2010 Dec; 49(12):829-40. PubMed ID: 21053992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.
    Herman GA; Stevens C; Van Dyck K; Bergman A; Yi B; De Smet M; Snyder K; Hilliard D; Tanen M; Tanaka W; Wang AQ; Zeng W; Musson D; Winchell G; Davies MJ; Ramael S; Gottesdiener KM; Wagner JA
    Clin Pharmacol Ther; 2005 Dec; 78(6):675-88. PubMed ID: 16338283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus.
    Addy C; Tatosian D; Glasgow XS; Gendrano IN; Kauh E; Martucci A; Johnson-Levonas AO; Selverian D; Matthews CZ; Gutierrez M; Wagner JA; Aubrey Stoch S
    Clin Ther; 2016 Mar; 38(3):516-30. PubMed ID: 26869191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
    O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
    Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
    Christopher R; Covington P; Davenport M; Fleck P; Mekki QA; Wann ER; Karim A
    Clin Ther; 2008 Mar; 30(3):513-27. PubMed ID: 18405789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-dose escalation study of yogliptin in healthy Chinese volunteers.
    Gou ZP; Wang ZL; Liang XF; Zheng L; Wang Y; Feng P
    Eur J Pharm Sci; 2019 Aug; 136():104950. PubMed ID: 31173870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once-Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, After Single and Multiple Doses in Healthy Subjects.
    Krishna R; Addy C; Tatosian D; Glasgow XS; Gendrano Iii IN; Robberechts M; Haazen W; de Hoon JN; Depré M; Martucci A; Peng JZ; Johnson-Levonas AO; Wagner JA; Stoch SA
    J Clin Pharmacol; 2016 Dec; 56(12):1528-1537. PubMed ID: 27225334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects.
    Park SI; Lee H; Oh J; Lim KS; Jang IJ; Kim JA; Jung JH; Yu KS
    Drug Des Devel Ther; 2015; 9():729-36. PubMed ID: 25678778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-in-Human, Single-Ascending Dose and Food Effect Studies to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cetagliptin, a Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus.
    Wang L; Lu J; Zhou S; Zhao Y; Xie L; Zhou C; Chen J; Ding S; Xie D; Ding J; Yu Q; Shen H; Hao G; Shao F
    Clin Drug Investig; 2021 Nov; 41(11):999-1010. PubMed ID: 34655432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males.
    Herman GA; Mistry GC; Yi B; Bergman AJ; Wang AQ; Zeng W; Chen L; Snyder K; Ruckle JL; Larson PJ; Davies MJ; Langdon RB; Gottesdiener KM; Wagner JA
    Br J Clin Pharmacol; 2011 Mar; 71(3):429-36. PubMed ID: 21284702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.